Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Gastrointestinal Cancer

Explore the latest updates, including expert interviews and features

The GI Cancer Channel on VJOncology is supported by Takeda. This supporter has no influence over the production of the content.

Latest videos VJSessions Subtypes Topics Conferences Features Editorial Board

Welcome to the Gastrointestinal Cancer Channel!

Catch up on the latest developments in gastrointestinal cancer with VJOncology, featuring exclusive interviews, podcasts, and expert-led roundtable discussions.

Genomic biomarkers in metastatic colorectal cancer

Subtypes

Gastric Cancer
Colorectal Cancer
Liver Cancer
Bile Duct Cancer
Pancreatic Cancer
3:24
S2303: nivolumab combo v paclitaxel + ramucirumab in PD-L1 CPS ≥ 1 gastric/esophageal adenocarcinoma
Anwaar Saeed • 17 Jan 2024
1:34
DESTINY-Gastric03: T-DXd in HER2+ and HER2-low gastric cancer
Yelena Y. Janjigian • 19 Jan 2024
3:34
FLOW + SPOTLIGHT: addressing nausea + vomiting in gastric cancer treatment with 1L zolbetuximab
Kohei Shitara • 19 Jan 2024
2:26
NIVO + chemo vs chemo as 1L treatment for advanced GC/GEJC/EAC: 4 year yr follow-up of CheckMate 649
Kohei Shitara • 19 Jan 2024
View All Videos
0:47
The key to precision medicine in colorectal cancer
Scott Kopetz • 8 Apr 2024
0:40
Clinical targeting of adaptive resistance in colorectal cancer
Scott Kopetz • 8 Apr 2024
1:47
Adaptive resistance in BRAF- and KRAS-mutated colorectal cancer
Scott Kopetz • 8 Apr 2024
1:19
How can we implement MRD testing in colorectal cancer?
Paolo Manca • 8 Apr 2024
View All Videos
0:54
Exploring durvalumab + bevacizumab + TACE in hepatocellular carcinoma: EMERALD-1 insights
Mark Yarchoan • 19 Jan 2024
0:51
EMERALD-1 trial: improved PFS w/ durvalumab + bevacizumab + TACE vs TACE in hepatocellular carcinoma
Lorenza Rimassa • 19 Jan 2024
1:15
MONTBLANC: sequential or up-front durvalumab, tremelimumab, + bevacizumab in unresectable HCC
Lorenza Rimassa • 19 Jan 2024
0:41
Therapeutic challenges in HCC: individualizing treatment decisions
Lorenza Rimassa • 20 Jan 2024
View All Videos
1:34
Brightline-2: brigimadlin as a 2L treatment for advanced cancers with MDM2 amplification and wtTP53
Changhoon Yoo • 18 Jan 2024
0:33
Advancing precision medicine: exploring ctDNA analysis beyond rectal cancer
Changhoon Yoo • 3 Jun 2023
2:47
Sub-analysis of STAMP trial: ctDNA as predictive biomarker for CCA monitoring during ACT
Changhoon Yoo • 3 Jun 2023
2:27
Advances in FGFR inhibition for hepatobiliary cancer
Arndt Vogel • 3 Jul 2023
View All Videos
0:40
The limited therapeutic efficacy of checkpoint inhibitors for pancreatic cancer
Olatunji Alese • 8 Apr 2024
0:48
Siltuximab and spartalizumab in advanced pancreatic adenocarcinoma
Olatunji Alese • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
1:54
Novel non-KRAS G12C inhibitors in solid tumors
Alexander Spira • 15 Mar 2024
View All Videos

Topics

Immuno-Oncology
CAR-T & Cellular Therapy
Trial Updates
Molecular Profiling
Radiotherapy
2:11
COMPASSION-15: cadonilimab in advanced gastric cancers
Yelena Janjigian • 8 Apr 2024
0:40
The limited therapeutic efficacy of checkpoint inhibitors for pancreatic cancer
Olatunji Alese • 8 Apr 2024
0:48
Siltuximab and spartalizumab in advanced pancreatic adenocarcinoma
Olatunji Alese • 8 Apr 2024
0:40
Clinical targeting of adaptive resistance in colorectal cancer
Scott Kopetz • 8 Apr 2024
View All Videos
1:53
SCG101: a novel T-cell therapy in advanced hepatitis B-related HCC
Ghassan Abou-Alfa • 22 Jun 2023
1:13
TACTIC-2: TAC01-HER2, a TAC T-cell therapy, in HER2+ tumors
Benjamin Schlechter • 4 Jun 2023
0:42
Treating HER2-positive solid tumors with TAC T-cell therapy
Benjamin Schlechter • 4 Jun 2023
0:41
How can immunotherapies successfully target MSS colorectal cancer?
Benny Johnson • 17 Apr 2023
View All Videos
2:11
COMPASSION-15: cadonilimab in advanced gastric cancers
Yelena Janjigian • 8 Apr 2024
0:48
Siltuximab and spartalizumab in advanced pancreatic adenocarcinoma
Olatunji Alese • 8 Apr 2024
1:01
KRYSTAL-1: adagrasib with cetuximab in KRAS G12C-mutated CRC
Scott Kopetz • 8 Apr 2024
6:16
PROOF 301: infigratinib vs. gem/cis in patients with CCA with an FGFR2 gene fusion/rearrangement
Ghassan K. Abou-Alfa • 19 Jan 2024
View All Videos
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
1:19
How can we implement MRD testing in colorectal cancer?
Paolo Manca • 8 Apr 2024
0:54
The current state of genomic profiling in colorectal cancer
Paolo Manca • 8 Apr 2024
1:58
Investigating genomic associations in metastatic colorectal cancer
Paolo Manca • 8 Apr 2024
View All Videos
1:00
Advancements in oligometastatic GI cancer management
Nataliya V. Uboha • 19 Jan 2024
1:03
Key considerations in the management of oligometastatic GI cancers
Nataliya V. Uboha • 19 Jan 2024
2:40
SANO-trial: neoadjuvant chemoradiotherapy vs. active Surveillance in esophageal cancer
Magnus Nilsson • 21 Oct 2023
2:34
Consolidation chemoradiation vs observation after 1L chemotherapy in advanced gall bladder cancers
Sushma Agrawal • 3 Jun 2023
View All Videos

Conferences

ESMO WCGIC
ASCO 2023
AACR 2023
GI Malignancies 2023
ASCO GI 2023
ASCO 2022
0:36
What are the current unmet needs in anal cancer?
Juan Manuel O'Connor • 30 Jun 2023
1:04
NCI9673: nivolumab with or without ipilimumab in anal cancer
Juan Manuel O'Connor • 30 Jun 2023
8:22
Colorectal trials at WCGIC 2023: VELO, DEEPER, IMPROVE and AVETRIC
Shouki Bazarbashi • 29 Jun 2023
2:41
The future of liquid biopsies in gastrointestinal malignancies
Filippo Pietrantonio • 29 Jun 2023
View All Videos
2:34
Consolidation chemoradiation vs observation after 1L chemotherapy in advanced gall bladder cancers
Sushma Agrawal • 3 Jun 2023
1:55
Belzutifan real-world vs clinical trial data: comparing efficacy and safety in VHL-associated tumors
Anusha Chidharla • 3 Jun 2023
1:28
Belzutifan as a non-invasive treatment option for VHL-associated tumors
Anusha Chidharla • 3 Jun 2023
2:09
Promising real-world outcomes of belzutifan in VHL-associated tumors
Anusha Chidharla • 3 Jun 2023
View All Videos
2:53
The emerging role of MRD in colorectal cancer decision making
Benny Johnson • 17 Apr 2023
1:12
Targeted therapies in metastatic colorectal cancer
Benny Johnson • 17 Apr 2023
1:19
Phase I/II trial of EP0031, a next generation selective RET inhibitor
Vivek Subbiah • 17 Apr 2023
1:05
Limitations in immune checkpoint inhibitors in treating gastric cancer
Yelena Janjigian • 18 Apr 2023
View All Videos
1:28
ctDNA testing in pancreatic cancer and other upper GI malignancies
Suneel Kamath • 4 Apr 2023
2:13
Ongoing clinical trials on using ctDNA results to guide GI cancer management
Suneel Kamath • 4 Apr 2023
3:03
The future of radiotherapy as a treatment for pancreatic cancer
Joseph Herman • 28 Mar 2023
4:04
Alliance trials: Combination of modified FOLFIRINOX and radiotherapy for pancreatic cancer
Joseph Herman • 28 Mar 2023
View All Videos
1:07
Updates in colorectal and rectal cancer at ASCO GI 2023
Ardaman Shergill • 26 Jan 2023
1:17
Detecting resistance to treatments in CRC with liquid biopsies
Ardaman Shergill • 26 Jan 2023
1:20
Advances in predicative biomarkers for rectal cancer
Ardaman Shergill • 26 Jan 2023
5:05
Is front-line anti-EGFR therapy essential in RAS-WT mCRC?
Ardaman Shergill • 26 Jan 2023
View All Videos
4:53
Phase I trial of mRNA neoantigen vaccines for pancreatic cancer
Vinod P. Balachandran • 16 Jun 2022
3:17
Development of individualized mRNA neoantigen vaccines for pancreatic cancer
Vinod Balachandran • 16 Jun 2022
1:31
Potential of immunotherapy for pancreatic cancer
Vinod P. Balachandran • 16 Jun 2022
1:13
Next steps for the development of individualised mRNA neoantigen vaccines
Vinod P. Balachandran • 16 Jun 2022
View All Videos
The GI Cancer Channel on VJOncology is supported by Takeda. This supporter has no influence over the production of the content.
The content of VJOncology is intended for healthcare professionals